An interventional study of ATTN201 focused ultrasound system in Chronic Pain, sponsored by Attune Neurosciences Inc. Recruiting at 2 sites in United States. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Attune Neurosciences Inc · Not applicable, Interventional, and Treatment
ATTN201 is a non-invasive focused ultrasound neurostimulation device that delivers offline MRI-guided non-invasive focused ultrasound to target brain areas. A cranial MRI is obtained before starting treatment while subjects wear a MR-compatible fiducial laced version of the wearable to co-register the cranial coordinate system with transducer coordinates. Simulations will define ultrasound focusing instructions for each patient to specifically target their brain area. For 100+ participants, we will also continuously monitor multiple interstitial pain biomarkers over the course of the intervention.
This is an open-label, single-arm study evaluating the safety, feasibility, and efficacy of delivering low intensity focused ultrasound stimulation of the centromedian nucleus of the thalamus (CMN) using the ATTN201 device for the treatment of chronic pain, with integrated multimodal biomarker monitoring.
Following informed consent and a screening (intake) visit, which may be completed either on a separate day before the first on-site visit or on the day of Visit 1 prior to any study procedures, participants will come in for Visit 1 (Day 0) for baseline measurements, safety assessments, MRI, and fitting of monitoring devices (Adaptyx Continuous Biomonitor, EEG, and smart watch; set up of all devices will be done after the MRI). Participants will receive 3 FUS treatments targeting the CMN on Days 3, 5-6, and 8-9; the two days immediately after the MRI/baseline visit (Days 1-2) are non-stimulation monitoring days that allow completion of offline MRI-guided targeting before the first treatment. Participants who do not achieve at least a 30% reduction in BPI-SF Pain Severity at Day 14 (non-responders) may be offered an optional extension of 3 additional sessions targeting the ventroposterolateral nucleus (VPL).
During the 14-day monitoring period (Day 0-14), participants will use multiple monitoring devices with varying durations:
Participants may report adverse events at any time through the Attune mobile application or through direct communication with the PI/study staff.
3,001 studies on the registry are indexed under Chronic Pain; 707 are open to participants now.
This study's planned enrollment of 120 is above the median of 60 across 2,212 interventional studies indexed under Chronic Pain.
Browse Chronic Pain studies →Attune Neurosciences Inc is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
3 required CMN FUS sessions on Days 2-3, 5-6, and 8-9; optional 3 additional VPL sessions
Device: ATTN201 focused ultrasound system
Head-worn low intensity focused ultrasound
Change in Brief Pain Inventory - Short Form (BPI-SF) Pain Severity Subscale Score
The Brief Pain Inventory - Short Form (BPI-SF) Pain Severity subscale is a 4-item self-report measure (worst pain, least pain, average pain, and current pain), each item rated on a 0 to 10 numeric rating scale anchored at 0 = "No pain" and 10 = "Pain as bad as you can imagine." The subscale score is the arithmetic mean of the 4 items and ranges from a minimum of 0 to a maximum of 10. Higher scores indicate greater pain severity, i.e., a worse outcome. Change is calculated as the Day 14 score minus the baseline score; a negative change indicates improvement.
Time frame: Baseline (Day 0) and Day 14
Change in Brief Pain Inventory - Short Form (BPI-SF) Pain Severity Subscale Score at Month 3
The Brief Pain Inventory - Short Form (BPI-SF) Pain Severity subscale is a 4-item self-report measure (worst pain, least pain, average pain, and current pain), each item rated on a 0 to 10 numeric rating scale anchored at 0 = "No pain" and 10 = "Pain as bad as you can imagine." The subscale score is the arithmetic mean of the 4 items and ranges from a minimum of 0 to a maximum of 10. Higher scores indicate greater pain severity, i.e., a worse outcome. This measure assesses durability of the treatment effect at Month 3, the key secondary timepoint.
Time frame: Baseline (Day 0) and Month 3
Change in Brief Pain Inventory - Short Form (BPI-SF) Pain Interference Subscale Score
The Brief Pain Inventory - Short Form (BPI-SF) Pain Interference subscale is a 7-item self-report measure assessing the degree to which pain interferes with general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Each item is rated on a 0 to 10 scale anchored at 0 = "Does not interfere" and 10 = "Completely interferes." The subscale score is the arithmetic mean of the 7 items and ranges from a minimum of 0 to a maximum of 10. Higher scores indicate greater interference from pain, i.e., a worse outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Patient Health Questionnaire-9 (PHQ-9) Total Score
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure of depressive symptom severity over the preceding two weeks. Each item is rated on a 0 to 3 scale anchored at 0 = "Not at all" and 3 = "Nearly every day." The total score is the sum of the 9 items and ranges from a minimum of 0 to a maximum of 27. Higher scores indicate more severe depressive symptoms, i.e., a worse outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Insomnia Severity Index (ISI) Total Score
The Insomnia Severity Index (ISI) is a 7-item self-report measure of insomnia severity, assessing difficulty falling asleep, difficulty staying asleep, early morning awakening, satisfaction with sleep, interference with daytime functioning, noticeability of impairment, and distress about sleep problems. Each item is rated on a 0 to 4 scale. The total score is the sum of the 7 items and ranges from a minimum of 0 to a maximum of 28. Higher scores indicate more severe insomnia, i.e., a worse outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Generalized Anxiety Disorder-7 (GAD-7) Total Score
The Generalized Anxiety Disorder-7 (GAD-7) is a 7-item self-report measure of anxiety symptom severity over the preceding two weeks. Each item is rated on a 0 to 3 scale anchored at 0 = "Not at all" and 3 = "Nearly every day." The total score is the sum of the 7 items and ranges from a minimum of 0 to a maximum of 21. Higher scores indicate more severe anxiety symptoms, i.e., a worse outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Depression Anxiety Stress Scales-8 (DASS-8) Total Score
The Depression Anxiety Stress Scales-8 (DASS-8) is an 8-item short-form self-report measure of depression, anxiety, and stress symptoms over the preceding week. Each item is rated on a 0 to 3 scale anchored at 0 = "Did not apply to me at all" and 3 = "Applied to me very much or most of the time." The total score is the sum of the 8 items and ranges from a minimum of 0 to a maximum of 24. Higher scores indicate greater depression, anxiety, and stress symptom burden, i.e., a worse outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Brief Resilience Scale (BRS) Score
The Brief Resilience Scale (BRS) is a 6-item self-report measure of the ability to recover from stress. Each item is rated on a 1 to 5 scale anchored at 1 = "Strongly disagree" and 5 = "Strongly agree"; three items are reverse-scored. The scale score is the arithmetic mean of the 6 items and ranges from a minimum of 1 to a maximum of 5. Higher scores indicate greater resilience, i.e., a better outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Flourishing Scale (FS) Total Score
The Flourishing Scale (FS) is an 8-item self-report measure of perceived success in areas such as relationships, self-esteem, purpose, and optimism. Each item is rated on a 1 to 7 scale anchored at 1 = "Strongly disagree" and 7 = "Strongly agree." The total score is the sum of the 8 items and ranges from a minimum of 8 to a maximum of 56. Higher scores indicate greater psychological well-being, i.e., a better outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Visual Analog Scale (VAS) Score for Sleepiness
Self-reported sleepiness rated on a 100 mm Visual Analog Scale (VAS) administered three times daily via the Attune mobile application. Scores range from a minimum of 0 mm ("Not at all sleepy") to a maximum of 100 mm ("Extremely sleepy"). Higher scores indicate greater sleepiness, i.e., a worse outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Interstitial Cortisol Concentration
Concentration of cortisol in dermal interstitial fluid, measured continuously by the Adaptyx Continuous Biomonitor, a microdialysis-based in-line analyzer, and reported in nanomoles per liter (nmol/L). Change is assessed as the difference from the participant's own baseline concentration. This is a descriptive biomarker measure; neither direction of change is designated a priori as a better or worse outcome.
Time frame: Baseline (Day 0) through Day 8-9 (continuous sampling)
Change in Electroencephalography (EEG) Absolute Spectral Power by Frequency Band
Absolute spectral power derived from continuous ambulatory electroencephalography (EEG) recorded with the Epitel REMI wireless EEG system in an 8-electrode (10-channel) configuration. Power is computed by fast Fourier transform in five canonical frequency bands, each reported separately in the common unit of microvolts squared per hertz (microV\^2/Hz): delta (0.5-4 Hz), theta (4-8 Hz), alpha (8-13 Hz), beta (13-30 Hz), and gamma (30-45 Hz). This is a descriptive biomarker measure; neither direction of change is designated a priori as a better or worse outcome.
Time frame: Baseline (Day 0) through Day 8-9 (continuous recording)
Change in Heart Rate Variability Measured as Root Mean Square of Successive Differences (RMSSD)
Heart rate variability quantified as the root mean square of successive differences between normal RR intervals (RMSSD), derived from photoplethysmography recorded by a consumer smart watch and reported in milliseconds (ms). This is a descriptive physiological measure; higher values reflect greater parasympathetic tone, and neither direction of change is designated a priori as a better or worse outcome.
Time frame: Baseline (Day 0) through Day 14 (continuous recording)
Change in Visual Analog Scale (VAS) Score for Mood
Self-reported mood rated on a 100 mm Visual Analog Scale (VAS) administered three times daily via the Attune mobile application. Scores range from a minimum of 0 mm ("Worst possible mood") to a maximum of 100 mm ("Best possible mood"). Higher scores indicate better mood, i.e., a better outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Visual Analog Scale (VAS) Score for Depression
Self-reported depressed feeling rated on a 100 mm Visual Analog Scale (VAS) administered three times daily via the Attune mobile application. Scores range from a minimum of 0 mm ("Not at all depressed") to a maximum of 100 mm ("Extremely depressed"). Higher scores indicate greater depressed feeling, i.e., a worse outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Visual Analog Scale (VAS) Score for Arousal
Self-reported arousal (alertness and activation) rated on a 100 mm Visual Analog Scale (VAS) administered three times daily via the Attune mobile application. Scores range from a minimum of 0 mm ("Not at all alert or activated") to a maximum of 100 mm ("Extremely alert or activated"). Higher scores indicate greater arousal; this measure is interpreted descriptively and neither direction of change is designated a priori as a better or worse outcome.
Time frame: Baseline (Day 0), Day 8, Day 14, Month 1, Month 2, Month 3, and Month 6
Change in Interstitial Kynurenine Pathway Metabolite Concentrations
Concentrations of the kynurenine pathway metabolites kynurenine, tryptophan, and quinolinic acid in dermal interstitial fluid, measured continuously by the Adaptyx Continuous Biomonitor, a microdialysis-based in-line analyzer. All three analytes share a common unit of measure, micromoles per liter (micromol/L), and each analyte is reported separately within this outcome measure. This is a descriptive biomarker measure; neither direction of change is designated a priori as a better or worse outcome.
Time frame: Baseline (Day 0) through Day 8-9 (continuous sampling)
Change in Electroencephalography (EEG)-Derived Sleep Duration Measures
Sleep duration parameters derived from continuous ambulatory electroencephalography (EEG) recorded with the Epitel REMI wireless EEG system and scored by a validated automated sleep-staging algorithm. All parameters share a common unit of measure, minutes, and each is reported separately: total sleep time, time in stage N1, time in stage N2, time in stage N3, and time in rapid eye movement (REM) sleep. Higher total sleep time indicates a better outcome; stage-specific durations are interpreted descriptively.
Time frame: Baseline (Day 0) through Day 8-9 (continuous recording)
Change in Electroencephalography (EEG)-Derived Sleep Efficiency
Sleep efficiency derived from continuous ambulatory electroencephalography (EEG) recorded with the Epitel REMI wireless EEG system, defined as total sleep time divided by time in bed and expressed as a percentage (%). Values range from a minimum of 0% to a maximum of 100%. Higher values indicate better sleep continuity, i.e., a better outcome.
Time frame: Baseline (Day 0) through Day 8-9 (continuous recording)
Change in Electroencephalography (EEG)-Derived Number of Nocturnal Awakenings
Number of nocturnal awakenings per night derived from continuous ambulatory electroencephalography (EEG) recorded with the Epitel REMI wireless EEG system and scored by a validated automated sleep-staging algorithm. Reported as a count of awakenings per night. Higher values indicate more fragmented sleep, i.e., a worse outcome.
Time frame: Baseline (Day 0) through Day 8-9 (continuous recording)
Change in Daily Step Count
Physical activity quantified as the number of steps taken per day, derived from accelerometry (actigraphy) recorded by a consumer smart watch and reported as a count of steps per day. Higher values indicate greater physical activity, i.e., a better outcome.
Time frame: Baseline (Day 0) through Day 14 (continuous recording)
Change in Walking Speed
Gait speed derived from accelerometry recorded by a consumer smart watch and reported in meters per second (m/s). Higher values indicate better ambulatory function, i.e., a better outcome.
Time frame: Baseline (Day 0) through Day 14 (continuous recording)
Change in Life-Space Area
Life-space range quantified as the area of the convex hull enclosing all locations visited per day, derived from GPS data recorded by a consumer smart watch and, for participants who opt in, the Beiwe research smartphone application. All coordinates are converted to relativistic coordinates referenced to the participant's modal home location before analysis, and no absolute GPS coordinates are stored or transmitted. Reported in square kilometers (km\^2). Higher values indicate greater community mobility, i.e., a better outcome.
Time frame: Baseline (Day 0) through Day 14 (continuous recording)
Change in Total Daily Distance Traveled
Total distance traveled per day, derived from GPS data recorded by a consumer smart watch and, for participants who opt in, the Beiwe research smartphone application, using relativistic coordinates referenced to the participant's modal home location. Reported in kilometers per day (km/day). Higher values indicate greater community mobility, i.e., a better outcome.
Time frame: Baseline (Day 0) through Day 14 (continuous recording)
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attune Neurosciences Inc